(Q42702317)

5 November 2017

Clinical drug interaction profile of idelalisib in healthy subjects (English)

1 reference

5 November 2017

Feng Jin

1

1 reference

5 November 2017

Michelle Robeson

2

1 reference

5 November 2017

Huafeng Zhou

3

1 reference

5 November 2017

Candra Moyer

4

1 reference

5 November 2017

Sibylle Wilbert

5

1 reference

5 November 2017

Bernard Murray

6

1 reference

5 November 2017

Srini Ramanathan

7

1 reference

5 November 2017

6 May 2015

1 reference

The Journal of Clinical Pharmacology

5 November 2017

1 reference

5 November 2017

55

1 reference

5 November 2017

909-919

1 reference

5 November 2017

8

1 reference

PI3K in lymphocyte development, differentiation and activation

5 November 2017

1 reference

Signalling by PI3K isoforms: insights from gene-targeted mice.

21 January 2018

1 reference

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia

21 January 2018

1 reference

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

21 January 2018

1 reference

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

21 January 2018

1 reference

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma

21 January 2018

1 reference

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities

21 January 2018

1 reference

Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes

21 January 2018

1 reference

Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.

21 January 2018

1 reference

Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin

21 January 2018

1 reference

Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine

21 January 2018

1 reference

Suitability of digoxin as a P-glycoprotein probe: implications of other transporters on sensitivity and specificity

21 January 2018

1 reference

Human P450 metabolism of warfarin

21 January 2018

1 reference

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

21 January 2018

1 reference

Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JCPH.495

1 reference

5 November 2017

1 reference